The (G>A) rs11573191 Polymorphism of PLA2G5 Gene Is Associated with Premature Coronary Artery Disease in the Mexican Mestizo Population: The Genetics of Atherosclerotic Disease Mexican Study

Coronary artery disease (CAD) is a multifactorial disorder that results from an excessive inflammatory response. Secretory phospholipase A2-V (sPLA2-V) encoded by PLA2G5 gene promotes diverse proinflammatory processes. The aim of the present study was to analyze if PLA2G5 gene polymorphisms are associated with premature CAD. Three PLA2G5 polymorphisms (rs11573187, rs2148911, and rs11573191) were analyzed in 707 patients with premature CAD and 749 healthy controls. Haplotypes were constructed after linkage disequilibrium analysis. Under dominant, recessive, and additive models, the rs11573191 polymorphism was associated with increased risk of premature CAD (OR = 1.51, P dom = 3.5 × 10−3; OR = 2.95, P rec = 0.023; OR = 1.51, P add = 1.2 × 10−3). According to the informatics software, this polymorphism had a functional effect modifying the affinity of the sequence by the MZF1 transcription factor. PLA2G5 polymorphisms were in linkage disequilibrium and the CGA haplotype was associated with increased risk of premature CAD (OR = 1.49, P = 0.0023) and with hypertension in these patients (OR = 1.75, P = 0.0072). Our results demonstrate the association of the PLA2G5 rs11573191 polymorphism with premature CAD. In our study, it was possible to distinguish one haplotype associated with increased risk of premature CAD and hypertension.

[1]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[2]  Enrico Petretto,et al.  Mapping genetic determinants of coronary microvascular remodeling in the spontaneously hypertensive rat , 2012, Basic Research in Cardiology.

[3]  S. Canizales-Quinteros,et al.  The ABCA1 Gene R230C Variant Is Associated with Decreased Risk of Premature Coronary Artery Disease: The Genetics of Atherosclerotic Disease (GEA) Study , 2012, PloS one.

[4]  J. Bonventre,et al.  Deletion of Secretory Group V Phospholipase A2 Attenuates Cell Migration and Airway Hyperresponsiveness in Immunosensitized Mice1 , 2007, The Journal of Immunology.

[5]  E. Dennis,et al.  The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. , 2000, Biochimica et biophysica acta.

[6]  W. Xing,et al.  Group V Secretory Phospholipase A2 Is Involved in Macrophage Activation and Is Sufficient for Macrophage Effector Functions in Allergic Pulmonary Inflammation , 2013, The Journal of Immunology.

[7]  M. Murakami,et al.  Diverse cellular localizations of secretory phospholipase A2 enzymes in several human tissues. , 2005, Biochimica et biophysica acta.

[8]  M. Murakami,et al.  Expression of secretory phospholipase A2 enzymes in lungs of humans with pneumonia and their potential prostaglandin-synthetic function in human lung-derived cells. , 2005, The Biochemical journal.

[9]  Y. Snitko,et al.  Mechanism of Human Group V Phospholipase A2(PLA2)-induced Leukotriene Biosynthesis in Human Neutrophils , 2001, The Journal of Biological Chemistry.

[10]  K. Forrest,et al.  The Capacity of Group V sPLA2 to Increase Atherogenicity of ApoE−/− and LDLR−/− Mouse LDL In Vitro Predicts its Atherogenic Role In Vivo , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[11]  G. Gyapay,et al.  Low-molecular-weight, calcium-dependent phospholipase A2 genes are linked and map to homologous chromosome regions in mouse and human. , 1996, Genomics.

[12]  A. Reiner,et al.  Novel Genetic Approach to Investigate the Role of Plasma Secretory Phospholipase A2 (sPLA2)-V Isoenzyme in Coronary Heart Disease: Modified Mendelian Randomization Analysis Using PLA2G5 Expression Levels , 2014, Circulation. Cardiovascular genetics.

[13]  Xavi García-Moll Marcadores de inflamación y de antiinflamación en el síndrome coronario agudo: ¿listos para usarlos en la práctica clínica? , 2005 .

[14]  S. Humphries,et al.  Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study. , 2007, Human molecular genetics.

[15]  N. Webb,et al.  Group V Secretory Phospholipase A2-modified Low Density Lipoprotein Promotes Foam Cell Formation by a SR-A- and CD36-independent Process That Involves Cellular Proteoglycans* , 2005, Journal of Biological Chemistry.

[16]  J. Kastelein,et al.  Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. , 2014, JAMA.

[17]  EvaHurt-Camejo,et al.  Localization of Nonpancreatic Secretory Phospholipase A2 in Normal and Atherosclerotic Arteries , 1997 .

[18]  N. Bazan,et al.  Expression and location of mRNAs encoding multiple forms of secretory phospholipase A2 in the rat retina , 2004, Journal of neuroscience research.

[19]  M. Lazdunski,et al.  Cloning, Chromosomal Mapping, and Expression of a Novel Human Secretory Phospholipase A2 * , 1997, The Journal of Biological Chemistry.

[20]  S. Hatakeyama,et al.  Analyses of Group III Secreted Phospholipase A2 Transgenic Mice Reveal Potential Participation of This Enzyme in Plasma Lipoprotein Modification, Macrophage Foam Cell Formation, and Atherosclerosis* , 2008, Journal of Biological Chemistry.

[21]  P. Cronet,et al.  Secretory Phospholipase A2 Group V: Lesion Distribution, Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  M. Willingham,et al.  Cell-specific expression of group X and group V secretory phospholipases A(2) in human lung airway epithelial cells. , 2000, American journal of respiratory cell and molecular biology.

[23]  M. Murakami,et al.  Cellular Distribution, Post-translational Modification, and Tumorigenic Potential of Human Group III Secreted Phospholipase A2* , 2005, Journal of Biological Chemistry.

[24]  C. Jordan,et al.  Group V Secretory Phospholipase A2 Promotes Atherosclerosis: Evidence From Genetically Altered Mice , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[25]  D. Fujioka,et al.  Group V Secretory Phospholipase A2 Reveals Its Role in House Dust Mite-Induced Allergic Pulmonary Inflammation by Regulation of Dendritic Cell Function , 2010, The Journal of Immunology.

[26]  Kei Yamamoto,et al.  Group X Secreted Phospholipase A2 Limits the Development of Atherosclerosis in LDL Receptor–Null Mice , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[27]  Katsutoshi Yamada,et al.  Potent Modification of Low Density Lipoprotein by Group X Secretory Phospholipase A2 Is Linked to Macrophage Foam Cell Formation* , 2002, The Journal of Biological Chemistry.

[28]  X. Garcia-Moll [Inflammatory and anti-inflammatory markers in acute coronary syndromes. Ready for use in the clinical setting?]. , 2005, Revista espanola de cardiologia.

[29]  J. Arm,et al.  Group V sPLA2: classical and novel functions. , 2006, Biochimica et biophysica acta.

[30]  B. Johansen,et al.  Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[31]  S. Humphries,et al.  Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. , 2006, Human molecular genetics.

[32]  M. Gelb,et al.  Cloning and recombinant expression of human group IIF-secreted phospholipase A(2). , 2000, Biochemical and biophysical research communications.

[33]  Katsutoshi Yamada,et al.  Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. , 2003, Biochimica et biophysica acta.

[34]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[35]  N. Fujii,et al.  Structures, Enzymatic Properties, and Expression of Novel Human and Mouse Secretory Phospholipase A2s* , 2000, The Journal of Biological Chemistry.

[36]  J. Qiao,et al.  Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2. , 1999, Arteriosclerosis, thrombosis, and vascular biology.